Inozyme Pharma
INZY
INZY was delisted on the 30th of June, 2025.
77 hedge funds and large institutions have $205M invested in Inozyme Pharma in 2023 Q3 according to their latest regulatory filings, with 13 funds opening new positions, 31 increasing their positions, 19 reducing their positions, and 10 closing their positions.
108% more call options, than puts
Call options by funds: $866K | Put options by funds: $416K
63% more repeat investments, than reductions
Existing positions increased: 31 | Existing positions reduced: 19
30% more first-time investments, than exits
New positions opened: 13 | Existing positions closed: 10
8% more capital invested
Capital invested by funds: $190M → $205M (+$14.4M)
4% more funds holding
Funds holding: 74 → 77 (+3)
1.37% more ownership
Funds ownership: 77.56% → 78.93% (+1.4%)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SC
Samlyn Capital
New York
|
+$16.5M |
| 2 |
EAM
Eventide Asset Management
Boston,
Massachusetts
|
+$15.9M |
| 3 |
Fidelity Investments
Boston,
Massachusetts
|
+$8.73M |
| 4 |
SB
Samsara BioCapital
Palo Alto,
California
|
+$7.95M |
| 5 |
Adage Capital Partners
Boston,
Massachusetts
|
+$6.55M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
DTC
Deep Track Capital
Greenwich,
Connecticut
|
-$9.16M |
| 2 |
Millennium Management
New York
|
-$4.47M |
| 3 |
WP
Woodline Partners
San Francisco,
California
|
-$1.61M |
| 4 |
Walleye Capital
New York
|
-$1.05M |
| 5 |
EI
EAM Investors
Solana Beach,
California
|
-$982K |
INZY Hedge Fund Activity: Q3 2023 in Review
77 of the 6,310 institutional investors tracked by Wall St. Rank reported a position in Inozyme Pharma (INZY) for Q3 2023, worth a combined $205M — up 7.6% from $190M a quarter earlier.
Buyers outnumbered sellers: 13 funds opened new INZY positions and 10 closed out — a net gain of 3 holders — while 31 added to existing stakes and 19 trimmed.
The largest buyer was Samlyn Capital, opening a new position worth an estimated $16.5M. The largest seller was Deep Track Capital, exiting entirely with an estimated $9.16M sold.
- 77 institutional investors held Inozyme Pharma (INZY) as of Q3 2023, up from 74 in Q2 2023.
- Funds reported $205M of Inozyme Pharma stock for Q3 2023, up 7.6% quarter-over-quarter.
- 13 funds opened new Inozyme Pharma positions in Q3 2023 and 10 closed out, a net change of +3 holders.
- The largest Inozyme Pharma buyer in Q3 2023 was Samlyn Capital, an estimated $16.5M added.
- The largest Inozyme Pharma seller in Q3 2023 was Deep Track Capital, an estimated $9.16M sold.
Based on aggregated 13F filings for Q3 2023.